Table 3.
Characteristics of individual patients
|
TACE | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient Number | Age | Gender | Etiology | AFP | # Tumors at Dx | Size (cm) pre-op | Within Milan | Pre-TACE Growth rate (cm/mo.) | Largest tumor dia by path | Days to Transplant* | Recur | Time to Recur |
Reasons for TACE |
|
| A | B | |||||||||||||
| T1 |
61 |
M |
Cryptogenic |
7254 |
1 |
6.3 |
N |
N/A |
5 |
241 |
N |
|
X |
|
| T2 |
50 |
M |
HCV |
27.9 |
1 |
3.5 |
Y |
0.02 |
3.7 |
327 |
Y |
14.5mo. |
|
X |
| T3 |
53 |
M |
HCV |
27.6 |
1 |
3.5 |
Y |
N/A |
5 |
263 |
N |
|
|
X |
| T4 |
54 |
M |
HCV |
67 |
3 |
2.9, 1.6, 1 |
Y |
N/A |
3 |
153 |
N |
|
|
X |
| T5 |
58 |
M |
HCV |
4 |
1 |
7.6 |
N |
0 |
7.6 |
82 |
N |
|
X |
|
| T6 |
59 |
M |
HCV |
4 |
2 |
3.1, 3.5 |
N |
0.03 |
3.5 |
127 |
N |
|
X |
|
| T7 |
65 |
F |
HBV |
667 |
1 |
2.5 |
Y |
0.33 |
2.5 |
167 |
N |
|
|
X |
| T8 |
68 |
F |
HCV |
18 |
1 |
6 |
N |
N/A |
4.7 |
174 |
N |
|
X |
|
| T9 |
57 |
M |
HCV |
43 |
2 |
3.2, 1.8 |
N |
N/A |
3.2 |
141 |
N |
|
X |
|
| T10 |
48 |
M |
HCV |
40 |
4 |
3.5, 2.8, 2.5, 1.0 |
N |
0.23 |
3.5 |
190 |
Y |
6mo. |
X |
|
| T11 |
49 |
M |
HCV |
2000 |
1 |
3.5 |
Y |
0.003 |
3.5 |
73 |
N |
|
|
X |
| T12 |
53 |
M |
HCV |
189 |
3 |
2.4, 0.6, 0.3 |
Y |
N/A |
2.4 |
377 |
N |
|
|
X |
| T13 |
54 |
M |
HCV |
8 |
5 |
2.1, 1.5, 1.4, 1, .7 |
N |
0 |
4 |
241 |
N |
|
X |
|
| T14 |
58 |
M |
HCV |
188 |
1 |
6.3 |
N |
0.12 |
5.5 |
345 |
Y |
13mo. |
X |
|
| T15 |
57 |
M |
HCV |
3 |
3 |
2.8, 1.9, 1.3 |
Y |
N/A |
2 |
263 |
Y |
18.5mo. |
|
X |
| T16 | 62 | M | HBV | 20 | 2 | 1.7, 1.6 | Y | 0 | 2 | 153 | N | X | ||
A = Downstage to achieve eligibility.
B = Bridge to transplant.
* = Days from HCC diagnosis to transplant.